HLA‐DP genes polymorphisms associate with hepatitis B surface antigen kinetics and seroclearance during nucleot(s)ide analogue therapy
暂无分享,去创建一个
Yoshiyuki Suzuki | M. Kobayashi | K. Ikeda | H. Kumada | Y. Arase | T. Hosaka | F. Suzuki | Y. Kawamura | H. Sezaki | N. Akuta | S. Saitoh | Taito Fukushima | M. Kobayashi
[1] M. Yuen,et al. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy , 2013, Hepatology.
[2] John F. Flaherty,et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study , 2013, The Lancet.
[3] Yoshiyuki Suzuki,et al. Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study , 2013, Journal of Gastroenterology.
[4] A. Koike,et al. Genome-Wide Association Study Confirming Association of HLA-DP with Protection against Chronic Hepatitis B and Viral Clearance in Japanese and Korean , 2012, PloS one.
[5] Hongbing Shen,et al. Genetic variants in human leukocyte antigen/DP‐DQ influence both hepatitis B virus clearance and hepatocellular carcinoma development , 2012, Hepatology.
[6] A. Berger,et al. A Common HLA-DPA1 Variant Is Associated with Hepatitis B Virus Infection but Fails to Distinguish Active from Inactive Caucasian Carriers , 2012, PloS one.
[7] Y. Kamatani,et al. A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population. , 2011, Human molecular genetics.
[8] Ding‐Shinn Chen,et al. Effect of Host and Viral Factors on Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Receiving Pegylated Interferon-α-2A Therapy , 2011, Antiviral therapy.
[9] E. Schadt,et al. Risk alleles for chronic hepatitis B are associated with decreased mRNA expression of HLA-DPA1 and HLA-DPB1 in normal human liver , 2011, Genes and Immunity.
[10] W. Tan,et al. Strong influence of human leukocyte antigen (HLA)‐DP gene variants on development of persistent chronic hepatitis B virus carriers in the Han Chinese population , 2011, Hepatology.
[11] D. Harnois,et al. Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B , 2011 .
[12] M. Manns,et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen–positive patients , 2010, Hepatology.
[13] M. Buti,et al. Early HBeAg Loss During Peginterferon α-2b Therapy Predicts HBsAg Loss: Results of a Long-Term Follow-Up Study in Chronic Hepatitis B Patients , 2009, The American Journal of Gastroenterology.
[14] Y. Kamatani,et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians , 2009, Nature Genetics.
[15] Huy Trinh,et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. , 2008, The New England journal of medicine.
[16] K. Simon,et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. , 2008, Gastroenterology.
[17] H. Tillmann,et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. , 2008, The New England journal of medicine.
[18] G. Liss,et al. Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B , 2008 .
[19] G. Makar. Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis BLai C-L, for the BEHoLD Al463027 Study Group (Queen Mary Hosp, Hong Kong; et al) N Engl J Med 354:1011–1020, 2006§ , 2007 .
[20] A. Cross,et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. , 2006, The New England journal of medicine.
[21] Ching-Lung Lai,et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. , 2006, The New England journal of medicine.
[22] R. D. de Man,et al. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon α-2b therapy , 2005, Gut.
[23] Pietro Andreone,et al. Clinical outcome of HBeAg‐negative chronic hepatitis B in relation to virological response to lamivudine , 2004, Hepatology.
[24] Man-Fung Yuen,et al. Viral hepatitis B , 2003, The Lancet.
[25] M. Wulfsohn,et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. , 2003, The New England journal of medicine.
[26] M. Wulfsohn,et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. , 2003, The New England journal of medicine.
[27] S. Nair,et al. Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: Is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? , 2001, Hepatology.
[28] N. Leung,et al. Chronic hepatitis B virus infection in Asian countries , 2000, Journal of gastroenterology and hepatology.
[29] E. Schiff,et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. , 1999, The New England journal of medicine.
[30] Ding‐Shinn Chen,et al. Hepatitis B Virus Infection , 2007 .